The North America Renal Denervation Market would witness Market growth of 34.6% CAGR during the forecast period (2022-2028).
Renal denervation (RDN) using a catheter has been shown in clinical trials to lower blood pressure and improve blood pressure control in people with resistant hypertension. The procedure's blood pressure-lowering effect may extend for up to 36 months. Despite the fact that RDN is a promising and growing method, additional evidence from clinical studies is needed to establish its long-term safety and efficacy when compared to the best available pharmaceutical treatment. It would also be critical to recognize the clinical characteristics of individuals who would gain the most from RDN, and the clinical characteristics of non-responders.
Because of changes in lifestyle that contribute to resistant hypertension as well as an increase in the existence of hypertension, the renal denervation industry has grown in size. Additionally, technical improvements have moved the renal denervation Market forward, resulting in the development of various new technologies for renal denervation systems, like micro-infusion. Moreover, the prevalence of hypertension has increased dramatically in recent years, causing blood pressure to fluctuate throughout the day, but if it stays high for an extended period of time, it can damage the patient's heart and cause health complications.
Hypertension increases the risk of heart disease and stroke, both of which are significant causes of death across the region. According to the Center for Disease Control and Prevention, hypertension was a primary or contributing reason to over half a million fatalities in the United States in 2019. In the United States, nearly half of people have hypertension, which is defined as systolic blood pressure higher than 130 mmHg or diastolic blood pressure higher than 80 mmHg, or are taking hypertension medication. Only around one-quarter of persons with hypertension have their condition under control.
Blood pressure of 140/90 mmHg or greater is found in nearly half of adults with uncontrolled hypertension. This comprises 37 million adults in the United States. Approximately 34 million people who have been advised to take medicine may require a prescription and start taking it.
The US Market dominated the North America Renal Denervation Market by Country in 2021, and would continue to be a dominant Market till 2028; thereby, achieving a Market value of $370.8 million by 2028. The Canada Market is anticipated to grow at a CAGR of 37.7% during (2022 - 2028). Additionally, The Mexico Market would display a CAGR of 36.5% during (2022 - 2028).
Based on Technology, the Market is segmented into Radiofrequency, Ultrasound, and Micro-Infusion. Based on End User, the Market is segmented into Hospitals, Specialty Clinics, and Others. Based on Product Type, the Market is segmented into Symplicity, Enlightn, Vessix, Paradise, Iberis, and Others. Based on countries, the Market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Renal Denervation Market is Estimated to reach $1.4 Billion by 2028, at a CAGR of 36.4%
The Market research report covers the analysis of key stake holders of the Market . Key companies profiled in the report include Abbott Laboratories, Boston Scientific Corporation, Medtronic PLC, Ablative Solutions, Inc., Mercator MedSystems, Inc., ReCor Medical, Inc., Renal Dynamics Limited, Johnson & Johnson, and Terumo Corporation.
By Technology
By End User
By Product Type
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
